Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search
Abingworth (company)

Abingworth (company)

Abingworth is a venture capital firm investing in seed-stage life sciences startups.

Abingworth is a venture capital firm founded in 1973. The firm's headquarters is located in London, United Kingdom, with additional offices in the United States at San Francisco and Boston. As of October 2019, Abingworth has sold off its ownership in 134 companies and is currently managing a portfolio of 25 companies.

Abingworth focuses on funding companies based in Europe and the United States. Sector-wise, Abingworth provides funding for companies in the life sciences industry, with a specific interest in fields such as biotherapeutics, small molecules, nucleic acid therapeutics, and vaccines. For each company, the firm allocates an investment total at a range of $15-$30 million.

Timeline

Invested in

Patents

Funding Rounds Participated In

Further Resources

Title
Author
Link
Type
Date

News

Title
Author
Date
Publisher
Description
Nick Paul
September 15, 2021
FierceBiotech
In 2017, Joël de Beer dropped out of his Ph.D. program and began trying to build a leading genetic medicines company from a site the size of a parking space. After working quietly for several years to realize the vision, de Beer's Anjarium Biosciences has now broken cover with 55.5 million Swiss francs from top-tier investors including Abingworth, Gimv and Pfizer Ventures.
Mark Terry
May 10, 2021
BioSpace
London-based venture capital fund Abingworth closed on a new Clinical Co-Development Fund now at $582 million. The fund's original target was just at $350 million.
Abingworth
May 10, 2021
www.prnewswire.com:443
/PRNewswire/ -- Abingworth, a leading international life sciences investment group, today announced the final closing of its new Clinical Co-Development Fund...
Nick Paul
May 7, 2021
FierceBiotech
Abingworth has raised $582 million for its second clinical co-development fund. The fund, ACCD 2, equips Abingworth to make triple-digit million investments in late-stage clinical programs.
Abingworth
February 3, 2021
www.prnewswire.com:443
/PRNewswire/ -- Abingworth, a leading international life sciences investment group, today announced the final closing of its latest transatlantic venture fund,...
SHOW MORE
Golden logo
By using this site, you agree to our Terms & Conditions.